Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann White

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Elife|March 27, 2018
Neurovascular sequestration in paediatric <i>P. falciparum</i> malaria is visible clinically in the retinaValentina Barrera, Ian James Callum MacCormick, Gabriela Czanner, et al.
BMC Medical Education|January 9, 2025
A blended learning approach for capacity strengthening to improve the quality of integrated HIV, TB, and malaria services during antenatal and postnatal care in LMICs: a feasibility studyAlice Norah Ladur, Uzochukwu Egere, Marion Ravit, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 9, 2024
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trialAlexander D Murphy, Catharine Porter, Ann White, et al.
American Journal of Lifestyle Medicine|November 14, 2024
Proposed Mechanisms and Associations of COVID-19 with Cardiometabolic Risk FactorsKoushik R Reddy, Kamil F Faridi, Monica Aggarwal, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 29, 2025
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trialAlexander D Murphy, Catharine Porter, Ann White, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2010
Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead explorationVibha Oza, Susan Ashwell, Patrick Brassil, et al.
Australian Health Review : a Publication of the Australian Hospital Association|August 7, 2024
Informing the management of the post-COVID condition: insights from the Western Australian experience comparing those who tested positive and negative to early COVID-19 strainsKristen Grove, Vinicius Cavalheri, HuiJun Chih, et al.
Eclinicalmedicine|June 24, 2026
Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UKRobert D Morgan, Catharine Porter, Cong Zhou, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Elife|March 27, 2018
Neurovascular sequestration in paediatric <i>P. falciparum</i> malaria is visible clinically in the retinaValentina Barrera, Ian James Callum MacCormick, Gabriela Czanner, et al.
BMC Medical Education|January 9, 2025
A blended learning approach for capacity strengthening to improve the quality of integrated HIV, TB, and malaria services during antenatal and postnatal care in LMICs: a feasibility studyAlice Norah Ladur, Uzochukwu Egere, Marion Ravit, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 9, 2024
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trialAlexander D Murphy, Catharine Porter, Ann White, et al.
American Journal of Lifestyle Medicine|November 14, 2024
Proposed Mechanisms and Associations of COVID-19 with Cardiometabolic Risk FactorsKoushik R Reddy, Kamil F Faridi, Monica Aggarwal, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 29, 2025
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trialAlexander D Murphy, Catharine Porter, Ann White, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2010
Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead explorationVibha Oza, Susan Ashwell, Patrick Brassil, et al.
Australian Health Review : a Publication of the Australian Hospital Association|August 7, 2024
Informing the management of the post-COVID condition: insights from the Western Australian experience comparing those who tested positive and negative to early COVID-19 strainsKristen Grove, Vinicius Cavalheri, HuiJun Chih, et al.
Eclinicalmedicine|June 24, 2026
Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UKRobert D Morgan, Catharine Porter, Cong Zhou, et al.
Pageof 8